bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of the “Sepsis Handbook”. This comprehensive book, produced by bioMérieux Editions, will be presented in a special preview at the International Sepsis Forum (ISF) held in Paris (Institut Pasteur), September 26-29, 2007.
Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment
17 September, 2007
bioMérieux and Ipsen announce today that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen.
Settlement between bioMérieux and Becton, Dickinson in the Field of Methicillin-resistant Staphylococcus aureus (MRSA) Detection
08 August, 2007
bioMérieux S.A. (Euronext: BIM) announced today that it has concluded a settlement on several licence agreements with GeneOhm Sciences Canada, a subsidiary of Becton, Dickinson and Company, in the field of Methicillin-resistant Staphylococcus aureus (MRSA) detection. This settlement, whose financial terms are confidential, follows arbitration proceedings that bioMérieux initiated against GeneOhm Sciences Canada in April 2007. Stéphane Bancel, Chief Executive Officer of bioMérieux, stated: “This settlement confirms the relevance of the intellectual property rights held by bioMérieux in this field. bioMérieux intends to play a major role in protecting patients from healthcare-associated infections, among which Methicillin-resistant Staphylococcus aureus (MRSA) are of critical concern for hospital clinicians.”
bioMérieux launches the first automated detection test for Clostridium difficile A and B toxins
24 Juli, 2007
A new, rapid, and effective solution in the fight against hospital-acquired (nosocomial)infections. bioMérieux, a world leader in the field of in vitro diagnostics, (Euronext : BIM) has just launched VIDAS® C. difficile Toxin A&B, a test for the detection of a bacterium responsible for fatal nosocomial epidemics in Canada, the United States and, more recently, in Europe.
Sysmex and bioMérieux Form a Global Partnership
02 Juli, 2007
Kobe (Japan), Marcy l'Etoile (France) - July 2, 2007. Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) and bioMérieux (Euronext: BIM) have signed an agreement today by which bioMérieux will become Sysmex’s global partner for distributing its UF-1000i urinalysis system in microbiology laboratories.
Healthcare-Associated Infections : First World Forum on a critical public health issue
30 Mai, 2007
bioMérieux organizes the First World Forum on Healthcare-Associated Infections (HAI). This Forum will bring together around fifty international experts at the Mérieux Foundation Conference Center (Les Pensières, Veyrier-du-Lac, France) from June 4th to 5th 2007.
